ERBB2 and breast carcinoma: The variation in serum CA15-3 concentrations, by breast cancer receptor status (HER2 + ; HR + and TNBC), was evaluated in an additional 174 breast cancer serum samples (see Supplementary Table 4) and is presented in Fig. 4.